KRASG12C-positive NSCLC and CRC
Two-dose, heterologous recombinant adenovirus vaccine
The vaccine is well-tolerated and easily administered.
With a reported 91.6% efficacy when administered per protocol but it does require storage at freezer temperatures.
Access our global intelligence, advanced analytics and global team of experts.